XOMA Fundamental Analysis - XOMA ROYALTY CORPORATION

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to XOMA. XOMA was compared to 557 industry peers in the Biotechnology industry. While XOMA is still in line with the averages on profitability rating, there are concerns on its financial health. XOMA shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

XOMA had negative earnings in the past year.

In the past year XOMA has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: XOMA reported negative net income in multiple years.

In multiple years XOMA reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -8.74%, XOMA belongs to the top of the industry, outperforming 85.15% of the companies in the same industry.

XOMA's Return On Equity of -21.96% is amongst the best of the industry. XOMA outperforms 84.08% of its industry peers.

Looking at the Return On Invested Capital, with a value of 0.19%, XOMA belongs to the top of the industry, outperforming 91.59% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-8.74%
ROE	-21.96%
ROIC	0.19%

ROA(3y)-14.85%

ROA(5y)-6.52%

ROE(3y)-31.32%

ROE(5y)-15.58%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

XOMA's Operating Margin of 1.03% is amongst the best of the industry. XOMA outperforms 91.95% of its industry peers.

The Profit Margin and Gross Margin are not available for XOMA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	1.03%
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XOMA is destroying value.

The number of shares outstanding for XOMA has been increased compared to 1 year ago.

XOMA has more shares outstanding than it did 5 years ago.

XOMA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -6.05, we must say that XOMA is in the distress zone and has some risk of bankruptcy.

XOMA has a worse Altman-Z score (-6.05) than 63.86% of its industry peers.

A Debt/Equity ratio of 1.18 is on the high side and indicates that XOMA has dependencies on debt financing.

With a Debt to Equity ratio value of 1.18, XOMA is not doing good in the industry: 78.71% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	1.18
Debt/FCF	N/A
Altman-Z	-6.05

ROIC/WACC0.02

WACC8.29%

2.3 Liquidity

A Current Ratio of 5.54 indicates that XOMA has no problem at all paying its short term obligations.

With a Current ratio value of 5.54, XOMA perfoms like the industry average, outperforming 57.42% of the companies in the same industry.

XOMA has a Quick Ratio of 5.54. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.

XOMA has a Quick ratio of 5.54. This is comparable to the rest of the industry: XOMA outperforms 58.50% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.54
Quick Ratio	5.54

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

XOMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.50%, which is quite impressive.

Looking at the last year, XOMA shows a very strong growth in Revenue. The Revenue has grown by 663.79%.

XOMA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.17% yearly.

EPS 1Y (TTM)52.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%106.98%

Revenue 1Y (TTM)663.79%

Revenue growth 3Y-9.28%

Revenue growth 5Y9.17%

Sales Q2Q%967.92%

3.2 Future

XOMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.94% yearly.

XOMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.09% yearly.

EPS Next Y73.1%

EPS Next 2Y42.15%

EPS Next 3Y39.94%

EPS Next 5YN/A

Revenue Next Year67.38%

Revenue Next 2Y38.13%

Revenue Next 3Y33.09%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

XOMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

With a Price/Forward Earnings ratio of 556.72, XOMA can be considered very expensive at the moment.

Compared to the rest of the industry, the Price/Forward Earnings ratio of XOMA indicates a rather cheap valuation: XOMA is cheaper than 87.30% of the companies listed in the same industry.

When comparing the Price/Forward Earnings ratio of XOMA to the average of the S&P500 Index (22.13), we can say XOMA is valued expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	556.72

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XOMA indicates a rather cheap valuation: XOMA is cheaper than 90.88% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	249.66

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates XOMA does not grow enough to justify the current Price/Earnings ratio.

XOMA's earnings are expected to grow with 39.94% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y42.15%

EPS Next 3Y39.94%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for XOMA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

XOMA ROYALTY CORPORATION

NASDAQ:XOMA (6/13/2025, 4:30:02 PM)

After market: 23.85 0 (0%)

23.85

-0.75 (-3.05%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-13 2025-05-13/bmo

Earnings (Next)08-11 2025-08-11

Inst Owners62.7%

Inst Owner Change0.49%

Ins Owners1.39%

Ins Owner Change-34.66%

Market Cap285.48M

Analysts82

Price Target65.96 (176.56%)

Short Float %1.5%

Short Ratio5.32

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0.47

Dividend Growth(5Y)N/A

DP-29.44%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)37.13%

Min EPS beat(2)-45.44%

Max EPS beat(2)119.7%

EPS beat(4)2

Avg EPS beat(4)56.23%

Min EPS beat(4)-256.98%

Max EPS beat(4)407.67%

EPS beat(8)3

Avg EPS beat(8)22.51%

EPS beat(12)3

Avg EPS beat(12)-16.39%

EPS beat(16)5

Avg EPS beat(16)-21.54%

Revenue beat(2)1

Avg Revenue beat(2)59.22%

Min Revenue beat(2)-2.38%

Max Revenue beat(2)120.82%

Revenue beat(4)3

Avg Revenue beat(4)39.22%

Min Revenue beat(4)-2.38%

Max Revenue beat(4)120.82%

Revenue beat(8)5

Avg Revenue beat(8)22.27%

Revenue beat(12)6

Avg Revenue beat(12)0.36%

Revenue beat(16)7

Avg Revenue beat(16)-7.52%

PT rev (1m)0%

PT rev (3m)-18.66%

EPS NQ rev (1m)-37.92%

EPS NQ rev (3m)-6.56%

EPS NY rev (1m)0%

EPS NY rev (3m)1.59%

Revenue NQ rev (1m)22.56%

Revenue NQ rev (3m)15.48%

Revenue NY rev (1m)36.77%

Revenue NY rev (3m)31.88%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	556.72
P/S	6.43
P/FCF	N/A
P/OCF	N/A
P/B	3.37
P/tB	4.82
EV/EBITDA	249.66

EPS(TTM)-1.14

EYN/A

EPS(NY)0.04

Fwd EY0.18%

FCF(TTM)-2.24

FCFYN/A

OCF(TTM)-0.55

OCFYN/A

SpS3.71

BVpS7.07

TBVpS4.95

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.74%
ROE	-21.96%
ROCE	0.24%
ROIC	0.19%
ROICexc	0.36%
ROICexgc	0.49%
OM	1.03%
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-14.85%

ROA(5y)-6.52%

ROE(3y)-31.32%

ROE(5y)-15.58%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	1.18
Debt/FCF	N/A
Debt/EBITDA	82.05
Cap/Depr	2651.64%
Cap/Sales	45.45%
Interest Coverage	0.04
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.54
Quick Ratio	5.54
Altman-Z	-6.05

F-Score5

WACC8.29%

ROIC/WACC0.02

Cap/Depr(3y)7738.51%

Cap/Depr(5y)4653.1%

Cap/Sales(3y)108.05%

Cap/Sales(5y)64.84%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)52.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%106.98%

EPS Next Y73.1%

EPS Next 2Y42.15%

EPS Next 3Y39.94%

EPS Next 5YN/A

Revenue 1Y (TTM)663.79%

Revenue growth 3Y-9.28%

Revenue growth 5Y9.17%

Sales Q2Q%967.92%

Revenue Next Year67.38%

Revenue Next 2Y38.13%

Revenue Next 3Y33.09%

Revenue Next 5YN/A

EBIT growth 1Y102%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year179.83%

EBIT Next 3Y51.02%

EBIT Next 5YN/A

FCF growth 1Y16.41%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y60.67%

OCF growth 3YN/A

OCF growth 5YN/A

XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens